- Moneycontrol /
- Market /
- Pharmaceuticals /
- NINE MONTHLY RESULTS
BSE Live
Feb 18, 16:00Prev. Close
504.90
Open Price
502.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 18, 15:59Prev. Close
506.05
Open Price
504.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
487.90 (5786)
| Nine Months Results of Strides Pharma Science (in Rs. Cr.) | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 | |
| Net Sales/Income from operations | 1,232.41 | 1,102.88 | 1,026.38 | 1,522.48 | 1,433.80 | |
| Other Operating Income | -- | -- | -- | 88.59 | 99.66 | |
| Total Income From Operations | 1,232.41 | 1,102.88 | 1,026.38 | 1,611.07 | 1,533.46 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 654.08 | 674.88 | 566.95 | 708.59 | 838.84 | |
| Purchase of Traded Goods | 26.51 | 16.45 | 34.15 | 84.78 | 51.66 | |
| Increase/Decrease in Stocks | 4.11 | -34.63 | 29.41 | -22.98 | -9.74 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 158.38 | 174.32 | 183.59 | 299.45 | 199.55 | |
| Depreciation | 68.48 | 61.49 | 60.44 | 92.95 | 75.61 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 241.27 | 210.65 | 201.64 | 345.77 | 280.77 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 79.58 | -0.28 | -49.80 | 102.51 | 96.77 | |
| Other Income | 72.90 | 58.20 | 139.36 | 118.86 | 130.81 | |
| P/L Before Int., Excpt. Items & Tax | 152.48 | 57.92 | 89.56 | 221.37 | 227.57 | |
| Interest | 48.39 | 37.78 | 70.53 | 85.76 | 68.25 | |
| P/L Before Exceptional Items & Tax | 104.09 | 20.14 | 19.03 | 135.61 | 159.33 | |
| Exceptional Items | -- | -2.01 | 22.43 | -92.57 | -24.08 | |
| P/L Before Tax | 104.09 | 18.13 | 41.46 | 43.04 | 135.24 | |
| Tax | 18.76 | 2.54 | -24.26 | 9.66 | 33.81 | |
| P/L After Tax from Ordinary Activities | 85.33 | 15.59 | 65.72 | 33.38 | 101.43 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -4.04 | 60.02 | -- | -- | |
| Net Profit/(Loss) For the Period | 85.33 | 11.55 | 125.74 | 33.38 | 101.43 | |
| Equity Share Capital | 89.55 | 89.55 | 89.50 | 89.37 | 89.27 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 9.53 | 1.29 | 7.35 | 3.74 | 12.62 | |
| Diluted EPS | 9.53 | 1.29 | 7.34 | 3.73 | 12.53 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 9.53 | 1.29 | 7.35 | 3.74 | 12.62 | |
| Diluted EPS. | 9.53 | 1.29 | 7.34 | 3.73 | 12.53 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- |
07.02.2020
Strides to acquire 18 abbreviated new drug applications from Pharmaceutics International, Inc
07.02.2020
Strides Pharma share price gains 3% after co acquires 18 ANDAs for US market
31.01.2020
Strides Pharma Standalone December 2019 Net Sales at Rs 364.47 crore, down 12.11% Y-o-Y
31.01.2020
Strides Pharma Consolidated December 2019 Net Sales at Rs 732.44 crore, down 7.81% Y-o-Y
31.01.2020
Strides Pharma Standalone December 2019 Net Sales at Rs 364.47 crore, down 12.11% Y-o-Y
31.01.2020
Strides Pharma Consolidated December 2019 Net Sales at Rs 732.44 crore, down 7.81% Y-o-Y
30.01.2020
Strides Pharma Standalone December 2019 Net Sales at Rs 364.47 crore, down 12.11% Y-o-Y
30.01.2020
Strides Pharma Consolidated December 2019 Net Sales at Rs 732.44 crore, down 7.81% Y-o-Y
